Empower Advisory Group’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$290K Sell
1,900
-410
-18% -$62.8K ﹤0.01% 424
2025
Q4
$318K Buy
2,310
+430
+23% +$56.3K ﹤0.01% 402
2025
Q3
$241K Buy
+1,880
New +$229K ﹤0.01% 475
2025
Q2
Sell
-2,306
Closed -$257K 516
2025
Q1
$257K Buy
+2,306
New +$245K ﹤0.01% 427
2024
Q1
Sell
-2,030
Closed -$205K 509
2023
Q4
$205K Sell
2,030
-579
-22% -$55.9K ﹤0.01% 459
2023
Q3
$266K Buy
2,609
+612
+31% +$62.1K ﹤0.01% 407
2023
Q2
$202K Buy
+1,997
New +$200K ﹤0.01% 467

Other funds holding NVS

Empower Advisory Group's NVS Position: Q1 2026 in Review

Empower Advisory Group reduced its Novartis (NVS) stake by 18% in Q1 2026, selling an estimated $62.8K and leaving 1,900 shares worth $290K. The position accounts for ﹤0.01% of the portfolio, ranked #424.

Empower Advisory Group first reported a position in NVS in Q2 2023 and has held it in 7 quarters since. The position peaked at $318K in Q4 2025. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Empower Advisory Group held 1,900 shares of Novartis worth $290K as of Q1 2026.
  • Empower Advisory Group sold 410 Novartis shares in Q1 2026, an estimated $62.8K.
  • Novartis made up ﹤0.01% of Empower Advisory Group's portfolio in Q1 2026, its #424 holding.
  • Empower Advisory Group first reported a position in Novartis in Q2 2023 and has held it in 7 quarters since.
  • Empower Advisory Group's Novartis position peaked at $318K in Q4 2025.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Empower Advisory Group's 13F filing for Q1 2026, filed 14 May 2026.